Infection of the central nervous system by Borna disease virus (BDV) provides a unique model to study the mechanisms whereby a persistent viral infection can impair neuronal function and cause behavioral diseases reminiscent of mood disorders, schizophrenia, or autism in humans. In the present work, we studied the effect of BDV infection on the response of hippocampal neurons, the main target for this virus, to the neurotrophin BDNF. We showed that persistent infection did not affect neuronal survival or morphology. However, it blocked BDNF-induced ERK 1/2 phosphorylation, despite normal expression of the TrkB BDNF receptor. In addition, BDNF-induced expression of synaptic vesicle proteins was abrogated, which resulted in severely impaired synaptogenesis and defects in synaptic organization. Thus, we provide the first evidence that a virus can interfere specifically with neurotrophin-regulated neuroplasticity, thereby hampering proper neuronal connectivity. These results may help to understand the behavioral disorders associated with BDV infection.
disorders, ranging from immune-mediated diseases (6) to behavioral alterations without inflammation (7) (8) (9) . In rats, BDV causes disturbances in learning, mood, and behavior reminiscent of those observed in human psychiatric diseases, such as schizophrenia, mood disorders, and autism (7) . Interestingly, serological evidence suggests that BDV, or a BDV-like virus, infects humans, although its role in psychiatric disorders remains controversial (10) (11) (12) (13) (14) (15) (16) .
The neurotrophins, including nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), and neurotrophin 3 and 4/5 (NT3 and NT 4/5), form a family of growth factors that regulate neuronal development, survival, and death (17) (18) (19) (20) . Two types of receptors mediate their actions: the Trk family, in which each isoform is matched to a given neurotrophin and p75, a universal neurotrophin receptor. Besides their classical implication in the differentiation and survival of specific populations of neurons, neurotrophins play fundamental roles in synaptic morphogenesis and function in brain regions relevant to learning and memory, such as the hippocampus (17) (18) (19) (20) . BDNF is especially important to regulate neuronal plasticity and to increase synaptic strength by inducing specific protein synthesis in dendrites (21, 22) .
The mechanism underlying BDV pathogenesis is not well understood (8) . In a previous study, we showed that BDV interferes with the response of PC12 cells to the neurotrophin NGF (23) . PC12 cells persistently infected with BDV did not differentiate into neuron-like cells upon stimulation with NGF. Based on this observation, we hypothesized that BDV may affect the response of neurons to neurotrophins also in vivo. BDV infects predominantly neurons of the Ammon's horn of hippocampus in CNS (24) . The main neurotrophin involved in the differentiation and survival of these neurons, as well as in regulating synaptic plasticity, is BDNF (21) . Therefore, we studied the consequences of BDV-persistent infection on the response of hippocampal neurons to BDNF. We show that BDV infects primary cultures of rat hippocampal neurons readily without causing any cytopathic effect. However, BDNF-triggered responses were severely impaired in BDV-infected neurons, leading to abrogated synaptogenesis. Our results show how a persistent viral infection can selectively interfere with the response of neurons to a neurotrophin without causing any cell death. This illustrates a novel aspect of virus/neuron interactions that may be relevant to the pathogenesis of neurobehavioral diseases.
MATERIALS AND METHODS

Cells and virus
Primary hippocampal pyramidal neurons (CA1-CA3) were prepared from 1-day-old SpragueDawley rats as described previously (25, 26) . Briefly, hippocampi were dissected and dissociated by mechanical trituration and digestion with 0.3% Aspergillus protease, followed by treatment with 1 mg/ml DNase. After adding 35% fetal calf serum (FCS), the suspension was filtered on a 70-µm cell strainer and centrifuged through a 4% BSA cushion. Thereafter, cells were seeded on poly-D L-ornithine (Sigma, St. Louis, MO), laminin (Roche, Basel, Switzerland)-coated glass coverslips, and grown in neurobasal medium supplemented with 25 mM β mercaptoethanol, 0.5 mM glutamine, 2% B-27 supplement (Gibco, Gaithersburg, MD), and 2% FCS. After 24 h, mitotic inhibitors 5-fluoro-2'-deoxyuridine (Sigma; 10 mg/ml) and uridine (Sigma; 25 mg/ml) were added to limit growth of glial cell contaminants. Neurons were infected by adding 500 focus-forming units (FFU) of cell-free BDV [strain He/80, prepared by osmotic shock treatment of persistently infected Vero cells (27) ] in the culture medium, corresponding to a multiplicity of infection of ~0.025 FFU/cell.
For viability studies, neurons from control and infected cultures were incubated for 30 min. at 37°C with 2.5 µg/ml propidium iodide (Sigma). Viable cells exclude the DNA dye, whereas necrotic and apoptotic cells exhibit red-fluorescent nuclei. The number of viable neurons was determined every 2 days in infected and control cultures, in 3 independent experiments.
Reagents and antibodies
BDNF (10 mg/ml stock solution) was from Research Diagnostics (Flanders, NJ) and propidium iodide (50 mg/ml stock solution) was from Sigma. BDV nucleoprotein (N) was detected with a rabbit polyclonal antibody and β-III tubulin; Tau and microtubule-associated protein 2 (MAP-2) were detected with specific monoclonal antibodies from Sigma. We also used a monoclonal antibody that recognized specifically the dually phosphorylated (activated) forms of mitogenactivated protein kinases ERK 1 and ERK 2 (pERK 1/2) (anti phospho-Thr 183 -Tyr 185 ERK, Sigma) and a rabbit polyclonal antibody recognizing total ERK 1 and ERK 2 (New England Biolabs, Beverly, MA). TrkB expression was assessed with the 794 sc-12 antibody (Santa Cruz Biotechnology Inc., Santa Cruz, CA). Antibodies specific for synaptic proteins synapsin-1, VAMP-2, and syntaxin-1 were from Synaptic Systems (Goettingen, Germany); the synaptophysin antibody was obtained from Chemicon (Temecula, CA). The antibody for postsynaptic marker PSD-95 was from Upstate Biotechnology (Lake Placid, NY). Secondary antibodies were from Jackson Immunoresearch (West Grove, PA) or Amersham (Piscataway, NJ).
Immunofluorescence and image analysis
Standard immunofluorescence was performed as described previously (23) . Briefly, cells grown on glass coverslips were fixed for 30 min at room temperature with 4% paraformaldehyde followed by methanol-acetone (50/50), rinsed with PBS, and blocked overnight at 4°C with PBS + 2% normal goat serum and 2% normal horse serum. Incubation for 1 h at room temperature or overnight at 4°C with primary antibodies was followed, after several washes in PBS, by a 1-h incubation at room temperature with secondary antibodies. After extensive washing, coverslips were mounted by using Vectashield (Vector Laboratories, Burlingame, CA). Image acquisition and off-line data analyses were performed by using resources available at the Centre d'Imagerie Dynamique (Institut Pasteur, Paris, France).
Imaging of pERK 1/2 was performed using procedures adapted from Wu et al. (28) . Neurons grown for 10 days in vitro were exposed to BDNF (50 ng/ml) for 10 min, rapidly fixed with 4% paraformaldehyde, and processed for double immunofluorescence with a polyclonal anti-BDV serum or Tau antibody (for control cultures) and the monoclonal antibody recognizing specifically pERK 1/2, as described previously (23) . Images were acquired with a confocal microscope, with constant laser power to avoid artifacts, which was adjusted for each series of experiments to make the best use of the eight-bit scale of the photomultipliers. Every identifiable neuron within a randomly selected field was included in the analysis. A minimum of 100 neurons was included for each experimental condition. The intensity of fluorescence was determined with image software from the National Institutes of Health (Bethesda, MD), and statistical analysis was performed with Statview (Cary, NC) software. Results from three separate experiments were pooled for statistical analysis using Student's t-test. The same analysis was performed to assess TrkB expression, after double immunofluorescence staining for TrkB and for either the BDV antigens (for infected cultures) or MAP-2.
To assess the number of synapses present in the cultures, control and infected neurons (treated or not with 50 ng/ml of BDNF from Days 7 to 11 in vitro) were processed for immunofluorescence using the presynaptic marker VAMP-2 and the postsynaptic marker PSD-95. Images were obtained with a fluorescence microscope using a 40× oil-immersion objective. For each experiment, double-labeled synaptic boutons were counted on a minimum of 10 randomly selected fields using Adobe Photoshop software (San Jose, CA). Simple PCI (C-imaging systems, Compix Inc., Tualatin, OR) was used for the acquisition and analysis of the size of double-stained synaptic structures. Data from three independent experiments were pooled for statistical analysis using Mann-Whitney's test.
Western blot analysis
Neuronal cultures were rapidly lysed in protein lysis buffer (23), containing 10 mM Tris-HCl, 50 mM NaCl, 30 mM sodium pyrophosphate, 50 mM NaF, 1 mM DTT, 1% Triton X100, 5 µM ZnCl 2 , 100 µM Na 3 VO 4 , and a tablet of Complete™ protease inhibitor cocktail (Roche). Insoluble material was removed by centrifugation (13,000 rpm for 20 min at 4°C), and protein concentration was determined by a Bradford assay (Bio-Rad protein assay, Hercules, CA). For each sample, the same amount of protein was electrophoresed on 12% SDS-PAGE (Invitrogen, Gaithersburg MD) gels before transfer onto Hybond C-extra membranes (Amersham). The membrane was blocked for 1 h at room temperature in Tris-buffered saline (TBS) containing 0.1% Tween 20 (TBST) and 5% bovine serum albumin or non-fat dry milk. Subsequently, the membrane was incubated overnight at 4°C with the primary antibodies diluted in blocking buffer. After washing with TBST, the blots were incubated 1 h with either biotinylated antirabbit or anti-mouse antibodies coupled to HRP (diluted 1:1000, Amersham). After extensive washing in TBST and TBS, peroxidase activity was revealed by using the Pierce Super signal substrate (Interchim, Montluçon, France). Chemiluminescent signals were quantified using a LAS-1000+ imager (Fuji, St. Quentin en Yvelines, France). When detecting the phosphorylated and the total form of ERK 1/2, the blots were first probed with the antibody specific for the phosphorylated form. After revelation, the blot was stripped by incubating in 0.1 M Glycine pH 2.5 at 60°C (20 min, twice), blocked as described above, and reprobed with the antibody recognizing all forms of the protein. Some experiments in which the same samples were run in duplicate and probed for pERK 1/2 and total ERK 1/2 gave identical results.
Electron microscopy
Neuronal cultures were prepared for electron microscopy analysis as described (29) . Briefly, infected and control cultures grown for 12-14 days in vitro (and treated or not with 100 ng/ml BDNF for 4 days) were fixed in 2.5% glutaraldehyde in 0.12 M phosphate buffer (PB), followed by post-fixation in 1% osmium tetroxide. After washing in PB, neurons were dehydrated in graded ethanol and flat-embedded in epon resin. Ultrathin sections were obtained in the synaptic plane (i.e., close to the bottom of culture dishes), counterstained with uranyl acetate and lead citrate and visualized with a Phillips TECNAI transmission electron microscope operated at 80 kV. Ultrastructural features of nerve terminals were analyzed and recorded on randomly selected fields by two independent investigators that were blind to culture conditions.
RESULTS
Characteristics of BDV infection and spread in hippocampal neurons
Primary hippocampal neurons were infected efficiently with BDV, and the infection spread rapidly in the culture, which was consistent with our previous observations (26) . By 9 days postinfection, nearly 100% of the neurons were infected, as determined by immunofluorescence staining for BDV antigens (Fig. 1A) . Remarkably, BDV infection had no cytopathic effect in the neuronal cultures, as determined by phase-contrast microscopy and propidium iodide staining. In addition, BDV infection did not affect the expression levels of neuron-specific structural markers, such as microtubule-associated protein 2 (MAP-2), Tau, or acetylated (β III) tubulin (Fig. 1B) .
Infection with BDV interferes with neurotrophin-triggered ERK 1/2 activation
Following binding to their Tyrosine kinase receptors (Trk), neurotrophins induce changes in gene expression of neurons in part by activating the Ras/MAPK (mitogen-activated protein kinase) cascade, which leads to the phosphorylation and activation of ERK 1 and ERK 2 (ERK 1/2; 30). Therefore, we examined the phosphorylation of ERK 1/2 in infected hippocampal neurons treated with BDNF, the main neurotrophin for these neurons. Because most phosphorylation events occur within minutes after addition of the neurotrophins, neurons were treated with BDNF for 10 min, and ERK 1/2 phosphorylation (pERK 1/2) was analyzed by immunofluorescence in control and virus-infected neurons, using an antibody specific for the activated (dually phosphorylated) form of ERK 1/2. To avoid artifacts, confocal immunocytochemical quantification was performed at a constant laser power for both infected and control neuronal cultures. Moreover, analysis included a large series of neurons selected at random in at least three independent experiments. This quantitative analysis revealed that BDNF-induced ERK 1/2 phosphorylation levels were severely reduced in infected neurons when compared with non-infected controls ( Fig. 2A, B) . In addition, analyzing pERK 1/2 and total ERK 1/2 expression by Western blotting confirmed the results obtained by immunofluorescence: The activation of ERK 1/2 by BDNF was decreased in infected neurons (Fig. 2C) . Reduced levels of pERK 1/2 also seem to occur prior to BDNF exposure. Interestingly, immunofluorescence and immunoblotting studies showed that the expression of TrkB receptor, the main mediator of ERK 1/2 activation following treatment with BDNF, was not affected by the infection (Fig. 2A, B , see also immunoblot in Fig. 3B ). Taken together, these data suggest that BDV interferes with neurotrophin-triggered ERK 1/2 phosphorylation downstream of TrkB. This interference appeared to be specific to the neurotrophin signaling pathway since the activation of ERK 1/2 was the same in control and BDV-infected neurons when the neurons were treated for 10 min with 200 µM H 2 O 2 , another stimulus that leads to a strong activation of ERK 1/2 (31; Data not shown).
BDV blocks BDNF-induced synaptic protein expression
Long-term exposure to neurotrophins increases the expression of synaptic vesicle proteins and of membrane-associated proteins involved in neurotransmitter release (32, 33) . Such neurotrophintriggered protein synthesis is essential for certain forms of synaptic plasticity (18) (19) (20) . Having shown that BDV inhibits the phosphorylation of ERK 1/2 in response to BDNF, we then asked whether this would affect the BDNF-induced expression of synaptic vesicle proteins (34) . Therefore, we analyzed the effect of BDV infection on the expression level of synapsin I, synaptophysin, synaptobrevin (VAMP-2), and syntaxin I. Immunocytochemical and Western blot analysis showed that the basal expression level of these proteins was not changed significantly by BDV infection (Fig. 3A, B) . When uninfected neurons were treated with BDNF for 4 days, quantitative analysis of Western blot signals (normalized to Tubulin expression levels) showed a 30-80% increase in the expression of synaptic proteins (Fig. 3C ), in accordance with previous reports (32, 33) . In contrast, this increase in expression following BDNF treatment did not occur in BDV-infected neurons. The expression levels of other neuronal markers such as Tubulin or TrkB receptor were not altered by BDV infection. Of interest, we also observed that long-term exposure to BDNF increased the level of viral proteins in neurons by ~25% (Fig. 3B,  C) . This is consistent with previous demonstrations that neurotrophins enhance BDV production in persistently infected cells (23, 35) .
BDV abrogates BDNF-induced synaptogenesis
Given the instrumental role of neurotrophins in promoting synaptogenesis (18, 36) , we next investigated whether the down-regulation of synaptic vesicle protein levels observed in BDVinfected neurons had an impact on the number and the size of the synapses in the cultures. Synapses were identified using double-label immunofluorescence for the presynaptic marker VAMP-2 and the postsynaptic marker PSD-95 (Fig. 4A) . The number of VAMP-2/PSD-95 double-positive boutons was determined in control and infected cultures, before and after treatment with BDNF. There was no obvious effect of viral infection on the number of synapses before exposure to BDNF. However, BDNF-induced synaptogenesis, which was clearly seen in control neuronal cultures, was totally abrogated in BDV-infected cultures (Fig. 4B) . We also measured the size of double-labeled synaptic boutons in control and virus-infected cultures not treated with BDNF (Fig. 4C) . Although their number was not affected, the synapses were significantly smaller in BDV-infected neurons, even in the absence of BDNF treatment.
Ultrastructural analysis of synapses in control and BDV-infected cultures
The smaller size of the synaptic boutons in BDV-infected neurons suggested that the infection may have disorganized the architecture of the synapses. Therefore, we examined the ultrastructure of the synapses using transmission electron microscopy. The sections were analyzed in duplicate by two investigators unaware of the experimental conditions. In control cultures, the typical ultrastructure of synapses (i.e., the clustering of synaptic vesicles in the vicinity of electron dense post-synaptic densities) was conspicuous (Fig. 5A ). After treatment with BDNF, the number of synapses was increased in sections from control samples. In infected cultures, there were significant alterations in the ultrastructure of the synapses (both pre-and post-synaptically), and their number did not increase in a detectable way after treatment with BDNF. The distribution of synaptic vesicles in the bouton of infected neurons was perturbed (Fig. 5B) . The synaptic vesicles were often found in clusters, accumulating in the synaptic bouton. Most of them appeared to be still associated with the actin cytoskeleton and were aggregated in crystal-like structures. A quantitative analysis done on a large number of synapses confirmed that the number of synaptic vesicles in the boutons of BDV-infected neurons was increased 3-to 4-fold compared with control neurons (Fig. 5C ).
DISCUSSION
Persistent, non-cytolytic infections by neurotropic viruses might have a role in human neurobehavioral diseases. Therefore, it is important to understand the mechanisms by which these viruses interfere with specific neuronal functions. The unique features of BDV, i.e., its exquisite tropism for neurons and its total lack of cytolytic effect, make it an especially relevant virus for these investigations. Recent evidence that BDV, or a BDV-like virus, can infect and persist in the human nervous system increases further the relevance of studying the pathogenesis of BDV infection, even if the implication of this virus in human behavioral diseases is still a matter of controversy.
In this work, we studied the impact of BDV-persistent infection on the response of hippocampal neurons, the main viral targets in vivo, to the neurotrophin BDNF. BDV infected these cultures efficiently, spreading to the whole neuronal population within 10 days. Moreover, BDV was remarkably non-cytopathic for these cells and the infection spread rapidly without impairing neuronal growth, survival, or the expression of neuron-specific markers such as MAP-2, Tau, or acetylated Tubulin. However, immunofluorescence and Western blot analysis showed that the virus interfered specifically with the BDNF-induced phosphorylation of ERK 1/2. It is likely that BDV interferes with the BDNF signaling cascade downstream of the TrkB receptor, because the level of expression of TrkB was unchanged by the infection. In addition, BDNF-induced synaptic protein synthesis and synaptogenesis were abrogated following chronic exposure to BDNF. Finally, the ultrastructure of synapses, in particular the distribution of synaptic vesicles within the boutons, was perturbed in infected neurons. There was a striking clustering of synaptic vesicles, apparently still bound to actin filaments. Two hypotheses may explain the disorganization of the synaptic ultrastructure seen in infected neurons. First, we showed that BDV decreases the expression of proteins that play important roles in synaptic vesicle cycling. Thus, altered cycling could lead to the accumulation of synaptic vesicles in the synaptic bouton. Second, the virus inhibits the activation of ERK 1/2. Because the release of the vesicles from actin filaments is triggered by the phosphorylation of synapsin I by pERK 1/2 (37, 38), the infection may prevent this release and cause an accumulation of actin bound vesicles.
The BDNF signaling pathway consists of a cascade of protein phosphorylation events leading to the phosphorylation of ERK 1/2 and its translocation to the nucleus where it activates secondary targets. Like all negative-strand viruses, BDV encodes a phosphoprotein (P), which is an important component of the viral replication complex. The phosphorylation of BDV P is performed by cellular kinases, including protein kinase c-epsilon and casein kinase II (39) . It is conceivable that BDV could also use kinase(s) located upstream of ERK 1/2 in the BDNF signaling pathway to phosphorylate P. If this were the case, BDV would hijack the neurotrophin signaling pathway to increase its replication. The consequence for the host-cell would be inhibition of BDNF-induced synaptogenesis. Interestingly, Fig. 3B shows that BDNF stimulation increased the level of expression of N, the major BDV nucleocapsid component. Also, Carbone et al. (35) and Hans et al. (23) showed that treating persistently infected cells with neurotrophins increases viral yield. Conversely, Planz et al. (40) , showed that a MEK 1/2 inhibitor blocks viral spread in culture. Neurons are the main BDV targets early in infection. One may speculate that this tropism is due to both efficient phosphorylation of BDV P by the neurotrophin signaling cascade and efficient trans-synaptic spread (26) . Finally, the preferential tropism of BDV for hippocampus and cerebellum early in infection and the specific damage to these these brain areas following neonatal infection could be due to the high level of neurotrophin expression in these CNS regions (41, 42).
We described previously the effect of BDV infection on the response of PC12 cells to the neurotrophin NGF (23) . Results from these two studies are not easy to compare because the cells differ. PC12 cells divide and respond to neurotrophins with a "stop" signal for proliferation and an "on" signal for differentiation. In this regard, they behave more like neuronal precursor cells. In differentiated hippocampal neurons, neurotrophins regulate physiological activity rather than fate. It is interesting to note that, in spite of this difference, BDV causes a blockade of the normal response to neurotrophins without altering receptor levels, and a lack of induction of synaptic proteins synthesis.
Brain performance depends on establishing, maintaining, and constantly remodeling precise synaptic connections between neurons. Neurotrophins such as BDNF play a major role in regulating synaptogenesis, both during development and in the adult CNS, as illustrated by the abnormal synaptogenesis observed in BDNF knockout mice (34, 43) . Impaired synaptogenesis can affect all brain functions, including cognition and behavior. In humans, reduced expression levels of synapsin were described in the hippocampus of patients with bipolar disorders and schizophrenia (44, 45) . In addition, impaired synaptic activity is now considered to cause the early cognitive deficits of many neurodegenerative diseases (46) . For example, in Alzheimer's disease, decreased synaptic density in the hippocampus and decreased amounts of presynaptic vesicle proteins correlate with the extent of cognitive impairment (47, 48) . In most cases, the cause of such synaptic alterations is unknown. Here, we show that a persistent non-cytopathic viral infection interferes with BDNF-induced synaptogenesis in primary cultures of hippocampal neurons. Because these neurons are the main viral target of BDV infection and persistence in vivo, this interference may play a central role in the postnatal brain dysgenesis and the behavioral disorders associated with BDV persistence.
Human psychiatric diseases have a complex origin that combines genetic and environmental factors. Our results raise the provocative possibility that, for some of them, these environmental factors include persistent, non-cytopathic viral infections. 2 ) and TrkB. Control (top row) or BDV-infected neurons (two bottom rows) were treated with BDNF and stained for pERK 1/2 or TrkB (left panels), in combination with either BDV nucleoprotein or Tau (two right panels) for, respectively, infected or control neurons. In the experiment shown here, cultures were fixed early after infection to display both infected and non-infected neurons in the same field. B) Quantitation of pERK 1/2 and TrkB. Levels of pERK 1/2 were measured as described in Materials and Methods on a minimum of 100 neurons, in control and BDV-infected cultures (11 days post-infection) after treatment with BDNF (50 ng/ml) for 10 min. The expression of TrkB was measured in control and infected neurons under the same conditions. Statistical analysis of signal intensities was performed with Student's t-test. Three independent experiments gave similar results. C) Immunoblots for pERK 1/2 and total ERK 1/2 in control (NI) or infected (BDV) cultures, before (-) and after (+) exposure to BDNF, showing results similar to those obtained with confocal immunocytochemical quantification. , red) . B) Quantitative analysis of the number of synapses present in control and BDV-infected cultures, with and without BDNF treatment. Synapses identified as described above were counted on a minimum of 10 randomly selected fields. Results from three separate experiments were combined to estimate the mean number of synapses per field for each experimental condition. NI-BDNF and BV-BDNF refer to control and BDV infected cultures that were exposed to BDNF for 4 days prior to analysis. Mann-Whitney statistical test: *P<0.05; **P<0.01. C) Analysis of synapse size distribution, as assessed with the Simple PCI image analysis software in non-infected and BDV-infected neurons. Note that this distribution is shifted to the left in BDV-infected neurons, indicating a reduction in the average size of the synapses. 
